BGM Group Ltd.
HealthcareNASDAQ:BGM · NASDAQ Global Market
+$0.03 today
Vol 0.42M · Avg 0.48M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.4%
avg 9.8%
ROIC
-0.9%
avg 6.9%
ROA
-2.7%
avg 4.2%
Analysis
ROIC is currently the strongest return metric at -0.9% versus its period average of 6.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chen Xin | CEO, VP of Duxiaobao Management Committee & Chairman | — | — | 32 | — | — |
Yuqing Li | Co-Chief Executive Officer | — | — | — | — | — |
Zhao Huandi | Co-Chief Executive Officer & Director | — | — | — | — | — |
Yaxuan Zhai | Chief Financial Officer | — | — | 30 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -15.3% | N/A — |
| Revenue | N/A | N/A | +4.3% | N/A — |
| Net Income | N/A | N/A | -15.2% | N/A — |
| EBIT | N/A | N/A | -26.3% | N/A — |
Analysis
Recent growth has been strongest in Revenue at +4.3% over three years.
Competitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$4.74B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Clover Health Investments, Corp.
NASDAQ:CLOV
$2.45B
Avadel Pharmaceuticals plc
AVDL
$2.12B
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
$1.86B
Mesoblast Limited
NASDAQ:MESO
$1.79B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.46B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
Who manages BGM?
BGM Group Ltd. (BGM) lists 4 active executives. The top listed executive is Chen Xin, CEO, VP of Duxiaobao Management Committee & Chairman.
Are BGM insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.